Novartis Inc

NVS

Equity

ISIN US66987V1098 / Valor 567514

New York Stock Exchange, Inc (2024-11-07)

USD 107.08+0.25%

Novartis Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Novartis Inc is a global pharmaceutical company known for its innovative medicines that aim to improve and extend people's lives. The company's Executive Committee oversees its business operations, which reach over 250 million people worldwide. Novartis focuses on reimagining medicine to empower patients, healthcare professionals, and societies in the fight against serious diseases.

Summarized from source with an LLMView SourceSector: Healthcare

Q2 2024 Net Sales

In Q2 2024, Novartis Inc reported net sales of USD 12,512 million, reflecting a 9% increase compared to Q2 2023. When adjusted for constant currencies, the growth rate was 11%.

Q2 2024 Operating Income

Novartis Inc's operating income for Q2 2024 was USD 4,014 million, a significant 43% increase from the USD 2,807 million reported in Q2 2023. On a constant currency basis, the growth was 47%.

Q2 2024 Net Income

For Q2 2024, Novartis Inc achieved a net income of USD 3,246 million, marking a 43% rise from the USD 2,271 million recorded in Q2 2023. The constant currency growth rate was 49%.

Q2 2024 Earnings Per Share (EPS)

Novartis Inc's earnings per share (EPS) for Q2 2024 stood at USD 1.60, up 47% from USD 1.09 in Q2 2023. When adjusted for constant currencies, the EPS growth was 52%.

Q2 2024 Free Cash Flow

In Q2 2024, Novartis Inc generated a free cash flow of USD 4,615 million, representing a 40% increase compared to the USD 3,292 million reported in Q2 2023.

Summarized from source with an LLMView Source

Key figures

14.1%1Y

28.0%3Y

23.1%5Y

Performance

16.2%1Y

18.4%3Y

20.5%5Y

Volatility